During the past decade, Kumamoto University Hospital conducted 82 clinical trials. In the 10-year time frame, 82 clinical trials started and 38 clinical trials were completed, i.e. on average, 46.3% percent of trials that started reached the finish line to date. In the past 5 years, 44 clinical trials started and 21 clinical trials were completed. i.e. 47.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kumamoto University Hospital" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Pfizer" with 12 trials sponsored, "Janssen Research & Development, LLC" with 9 trials sponsored, "Kumamoto University" with 8 trials sponsored and "Eli Lilly and Company" with 8 trials sponsored. Other sponsors include 65 different institutions and companies that sponsored additional 52 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kumamoto University Hospital" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Japan Clinical Oncology Group" with 2 trials as a collaborator, "Niigata University Medical & Dental Hospital" with 2 trials as a collaborator, "Alpha-A, Inc." with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Kumamoto University Hospital" are "Psoriasis" (5 trials), "Breast Cancer" (4 trials), "Carcinoma, Hepatocellular" (3 trials), "Heart Failure" (3 trials) and "Metastatic Breast Cancer" (3 trials). Many other conditions were trialed in "Kumamoto University Hospital" in a lesser frequency.

Most popular intervention types in "Kumamoto University Hospital" are "Drug" (107 trials), "Other" (9 trials), "Device" (4 trials), "Biological" (3 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (32 trials), "Bevacizumab" (5 trials), "Paclitaxel" (5 trials), "Rituximab" (5 trials) and "Atezolizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Kumamoto University Hospital" are 107 trials for "All" genders, 9 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Kumamoto University Hospital". undefined are not yet recruiting, 29 are recruiting, 33 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 49 completed trials in Kumamoto University Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Kumamoto University Hospital, 5 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 76 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 7 trials that are defined as “Not Applicable".

Kumamoto University Hospital has several departments that took part in Clinical trials: "Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University" - 6 trials, "Kumamoto City Hospital, Breast and Endocrine Surgery" - 4 trials, "Kumamoto University Faculty of Medical and Pharmaceutical Sciences" - 3 trials, "Kumamoto Shinto General Hospital; Breast Cancer Center" - 3 trials